Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H21N3O4 |
Molecular Weight | 367.3984 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=N)C1=CC=C(C=C1)C2=CC=C(OC[C@@H]3C[C@@H](CC(O)=O)C(=O)N3)C=C2
InChI
InChIKey=IKZACQMAVUIGPY-HOTGVXAUSA-N
InChI=1S/C20H21N3O4/c21-19(22)14-3-1-12(2-4-14)13-5-7-17(8-6-13)27-11-16-9-15(10-18(24)25)20(26)23-16/h1-8,15-16H,9-11H2,(H3,21,22)(H,23,26)(H,24,25)/t15-,16-/m0/s1
DescriptionSources: https://adisinsight.springer.com/drugs/800005284 | https://www.ncbi.nlm.nih.gov/pubmed/11250974https://www.ncbi.nlm.nih.gov/pubmed/9825033Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB04863 | https://clinicaltrials.gov/ct2/show/NCT02264119 | https://www.ncbi.nlm.nih.gov/pubmed/11154975 | https://www.ncbi.nlm.nih.gov/pubmed/11250974
Sources: https://adisinsight.springer.com/drugs/800005284 | https://www.ncbi.nlm.nih.gov/pubmed/11250974https://www.ncbi.nlm.nih.gov/pubmed/9825033
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB04863 | https://clinicaltrials.gov/ct2/show/NCT02264119 | https://www.ncbi.nlm.nih.gov/pubmed/11154975 | https://www.ncbi.nlm.nih.gov/pubmed/11250974
Lefradafiban, an orally active prodrug of fradafiban, is a novel glycoprotein (IIb/IIIa) inhibitor for the treatment of unstable angina. The pharmacokinetic and pharmacodynamic properties of lefradafiban were assessed in 130 healthy male volunteers who received a single dose of 10, 50, 75, 100, or 150 mg or multiple doses of 25, 50, 60, 75, 90, or 100 mg three times daily for one week. After both single and multiple doses, receptor occupancy and plasma lefradafiban levels correlated with platelet aggregation. Lefradafiban had been in phase II clinical trials by Boehringer Ingelheim for the treatment of thrombosis. However, it has been terminated.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093869 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10544919 |
|||
Target ID: CHEMBL2093869 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9286940 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
158 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11250974 |
30 mg 3 times / day steady-state, oral dose: 30 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FRADAFIBAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
314 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11250974 |
45 mg 3 times / day steady-state, oral dose: 45 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FRADAFIBAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
394 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11250974 |
60 mg 3 times / day steady-state, oral dose: 60 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
FRADAFIBAN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11102255
20, 30 and 45 mg t.i.d. of lefradafiban were used in phase II dose-escalation trial
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://circ.ahajournals.org/content/96/4/1130.short
One to 15 mg Fradafiban continuously infused over 30 minutes reversibly inhibited platelet aggregation in platelet-rich plasma ex vivo in response to 20 μmol/L ADP (5 mg, 100% inhibition at 27 minutes after administration) and to both 1.0 (5 mg, 100%) and 10 μg/mL (15 mg, 97±3%) collagen.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C263
Created by
admin on Fri Dec 15 16:39:04 GMT 2023 , Edited by admin on Fri Dec 15 16:39:04 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C107917
Created by
admin on Fri Dec 15 16:39:04 GMT 2023 , Edited by admin on Fri Dec 15 16:39:04 GMT 2023
|
PRIMARY | |||
|
7271
Created by
admin on Fri Dec 15 16:39:04 GMT 2023 , Edited by admin on Fri Dec 15 16:39:04 GMT 2023
|
PRIMARY | |||
|
SUB07813MIG
Created by
admin on Fri Dec 15 16:39:04 GMT 2023 , Edited by admin on Fri Dec 15 16:39:04 GMT 2023
|
PRIMARY | |||
|
DB06472
Created by
admin on Fri Dec 15 16:39:04 GMT 2023 , Edited by admin on Fri Dec 15 16:39:04 GMT 2023
|
PRIMARY | |||
|
148396-36-5
Created by
admin on Fri Dec 15 16:39:04 GMT 2023 , Edited by admin on Fri Dec 15 16:39:04 GMT 2023
|
PRIMARY | |||
|
DTXSID70163979
Created by
admin on Fri Dec 15 16:39:04 GMT 2023 , Edited by admin on Fri Dec 15 16:39:04 GMT 2023
|
PRIMARY | |||
|
73266
Created by
admin on Fri Dec 15 16:39:04 GMT 2023 , Edited by admin on Fri Dec 15 16:39:04 GMT 2023
|
PRIMARY | |||
|
66000
Created by
admin on Fri Dec 15 16:39:04 GMT 2023 , Edited by admin on Fri Dec 15 16:39:04 GMT 2023
|
PRIMARY | |||
|
100000080466
Created by
admin on Fri Dec 15 16:39:04 GMT 2023 , Edited by admin on Fri Dec 15 16:39:04 GMT 2023
|
PRIMARY | |||
|
CHEMBL3085474
Created by
admin on Fri Dec 15 16:39:04 GMT 2023 , Edited by admin on Fri Dec 15 16:39:04 GMT 2023
|
PRIMARY | |||
|
DQ0H2B8YKN
Created by
admin on Fri Dec 15 16:39:04 GMT 2023 , Edited by admin on Fri Dec 15 16:39:04 GMT 2023
|
PRIMARY | |||
|
C65769
Created by
admin on Fri Dec 15 16:39:04 GMT 2023 , Edited by admin on Fri Dec 15 16:39:04 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)